Oral sialic acid supplementation in NANS-CDG: Results of a single center, open label, observational pilot study.
Bibiche den HollanderMarion M BrandsLonneke de BoerCharlotte HaaxmaAnna LengyelPeter van EssenGera PetersHanneke J T KwastWillemijn M KleinKarlien L M CoeneDirk J LefeberClara D M van KarnebeekPublished in: Journal of inherited metabolic disease (2023)
The effect of sialic acid treatment may depend on the timing, with prenatal treatment potentially benefiting neurodevelopmental outcomes. Evidence is limited however, and longer-term follow-up in a larger number of prenatally treated patients is required. This article is protected by copyright. All rights reserved.
Keyphrases
- open label
- end stage renal disease
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- randomized controlled trial
- chronic kidney disease
- pregnant women
- cross sectional
- preterm infants
- adipose tissue
- type diabetes
- weight loss
- peritoneal dialysis
- radiation therapy
- metabolic syndrome
- combination therapy
- cell surface